会计学院知识库

       目前，就我国医药行业的发展现状来看，在我国各项政策的支持下，该行业
整体的发展速度较快。2020 年，我国在医疗卫生体制方面给予较高的重视，改革
持续推进，并且进一步深化，同时，医药行业的改革也在进行，涉及供给端、需
求端和支付端，另外，“三医联动”获得好的效果，合力促进医药行业不断发展。
医药企业要想在改革的过程中快速发展，其自身创新能力的提高是必不可少的，
企业若想创新，需要通过研究与开发活动作为途径，因此，企业应当重视研究与
开发活动。但是就现状分析，国内医药行业在研发方面的投入较低，和国外的企
业相比，差距较大。单独比较我国医药行业中各企业在研发方面的投入情况，总
的来看，恒瑞医药在研发上的投入较多，研发投入强度也较高，排在行业前列。
因此本文选择恒瑞医药为案例公司开展相关研究，探究研发投入对企业绩效有何
种影响，进而提高企业对研发的关注度，并给予重视，促使根据企业实际情况，
合理配置研发资源。
       本文首先介绍了恒瑞医药基本情况，运用销售收入增长率法和现金流组合法
判定案例公司当前处于生命周期哪一阶段，分析该公司在研发上的投入情况，既
有资金投入情况，也有人员投入情况。其次，探究研发投入对绩效形成何种影响。
       通过具体分析恒瑞医药公司中，研发投入对企业绩效的影响，本文获得如下
结论：成长期中研发投入对企业绩效影响不同；研发项目周期长，研发成果产出
慢；研发投入的效果存在滞后性。所以为了鼓励企业积极的加强研发活动，并且
让研发活动产生的效果更为显著，帮助企业增强核心竞争力，本文得出以下启示：提高研发投入力度；引进高端人才，提升员工素养；提高研发效率。

关键词：研发投入 企业绩效 医药行业 恒瑞医药

         At present, as far as the development status of my country's 
pharmaceutical industry is concerned, with the support of various policies 
in my country, the industry as a whole is developing rapidly. In 2020,my 
country attaches great importance to the health care system, and the reform 
continues to propel and further thorough. Meanwhile, the reform of the 
medicine industry is also in progress, including the supply side, the demand 
side and the payment side. In addition, the "three medical linkage" has 
achieved good results. Effectively, make a concerted effort to encourage 
the sustainable development of the pharmaceutical industry. If companies 
want to innovate, they need to take research and development activities as 
a way, and companies should attach importance to them. However, 
according to the analysis of the present situation, the domestic medicine 
industry's investment in research and development is relatively low, and 
the gap is relatively large compared with foreign companies. Comparing 
the investment in research and development of various enterprises in my 
country's pharmaceutical industry separately, in general, Hengrui 
pharmaceutical research and development investment more, research and 
development efforts are also high, ranking in the forefront of the industry. 
Thence, this paper chooses Hengrui Pharmaceutical as a case study 
company to look into the influence of R&D investment on enterprise 
performance, in order to increase the attention of enterprises to researchand development, and pay attention, and rationally allocate R&D according 
to the actual situation of the enterprise. 
          This article first introduces the fundamental state of Hengrui medicine, 
use the sales revenue growth rate method and cash flow combination 
method to decide the current life cycle stage of an enterprise, and invests 
in the company's R & D equipment, both capital investment and personnel 
investment. Secondly, explore the impact of R & D investment on 
performance.
         Through a specific analysis of the affect of R&D investment on 
enterprise performance in Hengrui Pharmaceutical Company, this paper 
receive the following conclusions: The impact of R & D investment on 
enterprise performance is different in the growth period; the cycle of R&D 
projects is long and the issuance of R&D results is slow; there is a lag in 
the influence of R&D investment. Therefore, in order to encourage 
enterprises to actively increase R&D activities and make the impact of 
R&D activities more significant, and to help firm enhance their core 
competitiveness, This paper draws the following enlightenment: Improve 
the investment in R & D; Introduce high-end talents and improve the 
quality of employees; Improve R & D efficiency.
Keywords: R & D investment; Enterprise performance; Pharmaceutical 
industry; Hengrui pharmaceutica